Products Affected - Description

• • Valganciclovir hydrochloride oral powder for solution, Camber, 50 mg/mL, 100 mL glass bottle, NDC 31722-0837-10
  • Valganciclovir hydrochloride oral tablet, Camber, 450 mg, bottle, 60 count, NDC 31722-0832-60
  • Valganciclovir hydrochloride oral tablet, Cipla USA, 450 mg, bottle, 60 count, NDC 69097-0277-03 - discontinued

Reason for the Shortage

• • Ajanta was not available to provide information.
  • Camber did not provide a reason for the shortage.
  • Cipla discontinued valganciclovir tablets.
  • Dr. Reddy's was not available to provide information.
  • Granules has valganciclovir powder for solution available.
  • H2 Pharma has Valcyte oral presentations available. Genentech transferred Valcyte to H2 Pharma (Cheplapharm's US partner) in April 2023.
  • Major has valganciclovir tablets available.
  • Somerset has valganciclovir powder for solution available.
  • Teva has valganciclovir powder for solution available.

Available Products

• • Valcyte oral powder for solution, H2 Pharma, 50 mg/mL, 100 mL glass bottle, NDC 61269-0485-10
  • Valcyte oral tablet, H2 Pharma, 450 mg, bottle, 60 count, NDC 61269-0480-60
  • Valganciclovir hydrochloride oral powder for solution, Granules, 50 mg/mL, 100 mL glass bottle, NDC 70010-0051-40
  • Valganciclovir hydrochloride oral tablet, Major, 450 mg, unit-dose blister pack, 20 count, NDC 00904-6796-10
  • Valganciclovir hydrochloride oral tablet, Major, 450 mg, unit-dose blister pack, 30 count, NDC 00904-6796-04
  • Valganciclovir hydrochloride oral powder for solution, Somerset Therapeutics LLC, 50 mg/mL, 100 mL glass bottle, NDC 70069-0810-01
  • Valganciclovir hydrochloride oral powder for solution, Teva, 50 mg/mL, 100 mL glass bottle, NDC 00591-2579-20

• • Camber has valganciclovir 450 mg tablets in 60 count bottles and 50 mg/mL powder for oral solution in 100 mL bottles on allocation.